Death receptor 4 (TRAIL-R1 or DR4) polymorphisms have been associated with cancer risk, but findingshave been inconsistent. To estimate the relationship in detail, a meta-analysis was here performed. A search ofPubMed was conducted to investigate the association between DR4 C626G, A683C and A1322G polymorphismsand cancer risk, using odds ratios (ORs) with 95% confidence intervals. The results suggested that DR4 C626Gand A683C polymorphisms were indeed associated with cancer risk (for C626G, dominant model, OR 0.991,95%CI 0.866-1.133, p=0.015; for A683C, additive model, OR=1.140, 95%CI: 0.948-1.370, p=0.028; dominantmodel, OR=1.156, 95%CI: 0.950-1.406, p=0.080) in the Caucasian subgroup. However, the association was notsignificant between DR4 polymorphism A1322G with cancer risk in Caucasians (For A1322G, additive model: OR1.085, 95%CI 0.931-1.289, p=0.217; dominant model: OR 1.379, 95%CI 0.934-2.035, p=0.311; recessive model:OR 1.026, 95%CI 0.831-1.268 p=0.429.). In summary, our finding suggests that DR4 polymorphism C626G andA683 rather than A1322G are associated with cancer risk in Caucasians.